Orally administered manganese with and without ascorbic acid as a liver-specific contrast agent and bowel marker for magnetic resonance imaging: Phase i clinical trial assessing efficacy and safety

Investigative Radiology

Volumn 45, Issue 9, 2010, Pages 559-564

  Leander, Peter ^a   Golman, Klaes ^b   Månsson, Sven ^a   Höglund, Peter ^c  

^a LUND UNIVERSITY   (Sweden)

^b Amersham Hlth Res and Devmt AB   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

contrast medium; liver; manganese; MRI; oral

Indexed keywords

ASCORBIC ACID; CONTRAST MEDIUM; MANGANESE; MANGANESE CHLORIDE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ASSESSMENT; CLINICAL CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG UPTAKE; GASTROINTESTINAL SYMPTOM; HEART RATE; HEMATOLOGY; HUMAN; HUMAN EXPERIMENT; LABORATORY; LIVER; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SMALL INTESTINE;

EID: 77955469625     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181e960ab     Document Type: Article

References (33)

1. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: US Multicenter Phase III study. Radiology. 2005;237:89-98.
2. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467.
3. Ba-Ssalamah A, Uffmann M, Saini S, et al. Clinical value of MRI liverspecific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol. 2009;19:342-357.
4. Marin D, Di Martino M, Guerrisi A, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumineenhanced MR imaging and multiphasic 64-section CT. Radiology. 2009;251: 85-95.
5. Kim YK, Kim CS, Lee YH, et al. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. Am J Roentgenol. 2004;182: 1217-1223.
6. Schmiedl UP, Nelson JA, Starr FL, et al. Hepatic contrast-enhancing properties of manganese-mesoporphyrin and manganese-TPPS4. Invest Radiol. 1992;27:536.
7. Wolf GL, Baum SL. Cardiovasvular toxicity and tissue proton T1 response to manganese injection in the dog and rabbit. Am J Roentgenol. 1983;141:193-197.
8. Leander P, Månsson S, Ege T, et al. CT and MR imaging of the liver using liver-specific CM: a comparative study in a tumour model. Acta Radiol. 1996;37:242-249. (Pubitemid 126709483)
9. Rofsky NM, Weinreb JC, Bernadino ME, et al. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. Radiology. 1993; 188:53-59.
10. Asplund A, Grant D, Karlsson JO. Mangafodipir (MnDPDP) and MnCl2-induced endothelium-dependent relaxation in bovine mesenteric arteries. J Pharmacol Exp Ther. 1994;271:609-614.
11. Brurok H, Ardenkjær-Larsen JH, Hansson G, et al. Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties. Biochem Biophys Res Commun. 1999;254:768-772.
12. Aicher KP, Laniado M, Kopp AF, et al. Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients. J Magn Reson Imaging. 1993;3:731-737.
13. Mamourian AC, Burnett KR, Goldstein EJ, et al. Proton relaxation enhancement in tissue due to ingested manganese chloride: time course and dose response in rat. Physiol Chem Phys Med NMR. 1984;16:123-128.
14. Cory DA, Schwartzentruber DJ, Mock BH. Ingested manganese chloride as a contrast agent for magnetic resonance imaging. Magn Reson Imaging. 1987; 5:65-70.
15. Kreft BP, Baba Y. Tanimoto, et al. Orally administered manganese chloride: enhanced detection of hepatic tumors in rats. Radiology. 1993;186:543-548.
16. Pettersson G, Månsson S. Orally administered manganese chloride and ascorbic acid as a putative contrast agent for magnetic resonance imaging of the liver. Nycomed Innovation 1995; Internal report WSL-001.
17. Thomsen HS, Svendsen O, Klastrup S. Increased manganese concentration in the liver after oral intake. Acad Radiol. 2004;11:38-44.
18. Rief M, Huppertz A, Asbach P, et al. Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement. Invest Radiol. 2010;45:565-571.
19. Chabanova E, Thomsen HS, Logager V, et al. Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0. 23, 0.6 and 1.5T MRI, a part of a phase I trial. MAGMA. 2004;17:28-35.
20. Shaw DD. Summary of the clinical experience with S095 injection (manganese dipyridoxyl diphosphate, MnDPDP). In: Rinck PA, Muller RN, eds. New Developments in Contrast Agent Research. Proceedings of the 3rd Special Topic Seminar of the European Magnetic Resonance Forum. Mons, Belgium: EMRF; 1992:1-15.
21. Torres CG, Lundby B, Sterud AT, et al. MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol. 1997;38:631-637.
22. Hauser RA, Zesiewicz TA, Rosemurgy AS, et al. Manganese intoxication and chronic liver failure. Ann Neurol. 1994;36:871-875.
23. Pauling L. Evolution and the need for ascorbic acid. Proc Natl Acad Sci USA. 1970;67:1643-1648.
24. Korc M. Manganese homeostasis in humans and its role in disease states. In: Prasad AS, ed. Essential and Toxic Trace Elements in Human Health and Disease. New York, NY: Alan R. Liss, Inc; 1988:253-273.
25. Sanderson IR, Walker WA. Uptake and transport of macromolecules by the intestine: possible role in clinical disorders (an update). Gastroenterology. 1993;104:622-639.
26. Rofsky NM, Weinreb JC. Manganese (II) N,N-dipyridoxylethylenediamine-N,N- diacetate 5,5-bis(phosphate): clinical experience with a new contrast agent. Magn Reson Q. 1992;8:156.
27. Bottomley PA, Foster TH, Argersinger RE, et al. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys. 1984;11:425.
28. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. Am J Roentgenol. 1990;155:943.
29. Ferrucci JT, Freeny PC, Stark DD, et al. Symposium: advances in hepatobiliary radiology. Radiology. 1988;168:319-338.
30. van Lom K, Brown JJ, Perman WH. Liver imaging at 1.5 tesla: pulse sequence optimization based on improved measurement of tissue relaxation times. Magn Reson Imaging. 1991;9:165-171.
31. Pettersson G, Månsson S. Comparison of intravenously injected Mn-DPDP with orally administered manganese chloride- ascorbic acid on the signal intensity of T1-weighted spin-echo magnetic resonance images of rat liver. Nycomed innovation 1995; Internal report WSL-002.
32. Nelson RC, Chezmar JL, Sugarbaker PH, et al. Preoperative localization of focal liver lesions to specific liver segments: utility of CT during arterial portography. Radiology. 1990;176:89-94.
33. Nelson RC, Thompson GH, Chezmar JL, et al. CT during arterial portography: diagnostic pitfalls. Radiographics. 1992;12:705-718.